Feedback
ZYDUSLIFE 
Reputation: 642,681 • Aug 14, 2023 5:48 PM
Zydus Lifesciences down, Nuvama downgrades stock despite a strong Q1
Nuvama downgrades Zydus to ‘hold’. It says Q1 results are unlikely to be repeated, as exclusivity of epilepsy drug Trokendi is declining and revenue from blood cancer drug Revlimid remains 'lumpy'
Moneycontrol
Vote
Comment
1 Share
NSE:ZYDUSLIFE price when posted: 641.9